Phase II Single Arm Study of AZD9291 to Treat NSCLC Patients in Asia Pacific

Summary

A Phase II, Open Label, Single-arm Study to Assess the Safety and Efficacy of AZD9291 in Asia Pacific Patients with Locally Advanced/Metastatic Non-Small Cell Lung Cancer whose Disease has Progressed with Previous Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Therapy and whose Tumours harbour a T790M mutation within the Epidermal Growth Factor Receptor Gene

Timeline

Start

2015-06-22

Primary completion

2016-03-04

Completion

2025-11-28

Drugs

Indications